B-intervention	0	14	Bisphosphonate
O	15	24	treatment
O	25	27	in
O	28	35	primary
O	36	42	breast
O	43	49	cancer
O	49	50	:
O	51	58	results
O	59	63	from
O	64	65	a
O	66	76	randomised
O	77	87	comparison
O	88	90	of
O	91	95	oral
O	96	107	pamidronate
O	108	114	versus
O	115	117	no
O	118	129	pamidronate
O	130	132	in
O	133	141	patients
O	142	146	with
O	147	154	primary
O	155	161	breast
O	162	168	cancer
O	168	169	.

O	170	176	During
O	177	180	the
O	181	187	period
O	188	192	from
O	193	200	January
O	201	205	1990
O	206	208	to
O	209	216	January
O	217	221	1996
O	222	223	a
O	224	229	total
O	230	232	of
B-total-participants	233	236	953
B-eligibility	237	245	patients
I-eligibility	246	250	with
I-eligibility	251	256	lymph
I-eligibility	257	261	node
I-eligibility	262	270	negative
I-eligibility	271	278	primary
I-eligibility	279	285	breast
I-eligibility	286	292	cancer
O	293	297	were
O	298	308	randomised
O	309	311	to
O	312	316	oral
O	317	328	pamidronate
O	329	330	(
O	330	331	n
O	331	332	=
B-intervention	332	335	460
O	335	336	)
O	337	340	150
O	341	343	mg
O	344	349	twice
O	350	355	daily
O	356	359	for
O	360	361	4
O	362	367	years
O	368	370	or
B-control	371	373	no
I-control	374	382	adjuvant
I-control	383	394	pamidronate
O	395	396	(
O	396	397	n
O	397	398	=
B-control-participants	398	401	493
O	401	402	)
O	403	405	in
O	406	411	order
O	412	414	to
O	415	426	investigate
O	427	434	whether
O	435	439	oral
O	440	451	pamidronate
O	452	455	can
O	456	463	prevent
O	464	467	the
O	468	478	occurrence
O	479	481	of
O	482	486	bone
O	487	497	metastases
O	498	501	and
O	502	511	fractures
O	511	512	.

O	513	516	The
O	517	525	patients
O	526	534	received
O	535	543	adjuvant
O	544	556	chemotherapy
O	556	557	,
O	558	562	loco
O	562	563	-
O	563	571	regional
O	572	581	radiation
O	582	589	therapy
O	589	590	,
O	591	594	but
O	595	597	no
O	598	607	endocrine
O	608	617	treatment
O	617	618	.

O	619	625	During
O	626	629	the
O	630	636	follow
O	636	637	-
O	637	639	up
O	640	646	period
O	647	650	the
B-outcome	651	657	number
I-outcome	658	660	of
I-outcome	661	669	patients
I-outcome	670	674	with
I-outcome	675	679	pure
I-outcome	680	684	bone
I-outcome	685	695	metastases
O	696	699	was
B-cv-bin-abs	700	702	35
O	703	705	in
O	706	709	the
O	710	717	control
O	718	723	group
O	724	727	and
B-iv-bin-abs	728	730	31
O	731	733	in
O	734	737	the
O	738	749	pamidronate
O	750	755	group
O	755	756	.

O	757	760	The
B-outcome	761	767	number
I-outcome	768	770	of
I-outcome	771	779	patients
I-outcome	780	784	with
I-outcome	785	786	a
I-outcome	787	798	combination
I-outcome	799	801	of
I-outcome	802	806	bone
I-outcome	807	810	and
I-outcome	811	816	other
I-outcome	817	824	distant
I-outcome	825	835	metastases
O	836	840	were
B-cv-bin-abs	841	843	22
O	844	846	in
O	847	850	the
O	851	858	control
O	859	864	group
O	865	868	and
B-iv-bin-abs	869	871	20
O	872	874	in
O	875	878	the
O	879	890	pamidronate
O	891	896	group
O	896	897	.

O	898	901	The
O	902	908	hazard
O	909	913	rate
O	914	919	ratio
O	920	923	for
B-outcome	924	934	recurrence
I-outcome	935	937	in
I-outcome	938	942	bone
O	943	945	in
O	946	949	the
O	950	961	pamidronate
O	962	967	group
O	968	976	compared
O	977	979	to
O	980	983	the
O	984	991	control
O	992	997	group
O	998	1001	was
O	1002	1003	1
O	1003	1004	.
O	1004	1006	03
O	1007	1008	(
O	1008	1010	95
O	1010	1011	%
O	1012	1022	confidence
O	1023	1031	interval
O	1032	1033	0
O	1033	1034	.
O	1034	1036	75
O	1036	1037	-
O	1037	1038	1
O	1038	1039	.
O	1039	1041	40
O	1041	1042	)
O	1043	1046	and
O	1047	1048	p
O	1048	1049	=
O	1049	1050	0
O	1050	1051	.
O	1051	1053	86
O	1053	1054	.

O	1055	1057	No
O	1058	1064	effect
O	1065	1068	was
O	1069	1077	observed
O	1078	1080	on
B-outcome	1081	1088	overall
I-outcome	1089	1097	survival
O	1097	1098	.

O	1099	1101	In
O	1102	1103	a
O	1104	1109	small
O	1110	1118	subgroup
O	1119	1121	of
O	1122	1124	27
O	1125	1133	patients
O	1134	1138	from
O	1139	1142	the
O	1143	1148	study
O	1148	1149	,
O	1150	1152	12
O	1153	1155	of
O	1156	1160	whom
O	1161	1165	were
O	1166	1173	treated
O	1174	1178	with
O	1179	1190	pamidronate
O	1191	1192	a
O	1193	1204	significant
O	1205	1209	bone
O	1210	1220	preserving
O	1221	1227	effect
O	1228	1231	was
O	1232	1240	observed
O	1241	1243	on
B-outcome	1244	1248	bone
I-outcome	1249	1256	mineral
I-outcome	1257	1264	density
I-outcome	1265	1267	in
I-outcome	1268	1271	the
I-outcome	1272	1278	lumbar
I-outcome	1279	1284	spine
O	1284	1285	,
O	1286	1289	but
O	1290	1293	not
O	1294	1296	in
O	1297	1300	the
O	1301	1309	proximal
O	1310	1315	femur
O	1315	1316	.

O	1317	1320	The
O	1321	1328	results
O	1329	1333	from
O	1334	1337	the
O	1338	1343	trial
O	1344	1346	do
O	1347	1350	not
O	1351	1358	support
O	1359	1360	a
O	1361	1371	beneficial
O	1372	1378	effect
O	1379	1381	of
O	1382	1386	oral
O	1387	1398	pamidronate
O	1399	1401	on
O	1402	1405	the
O	1406	1416	occurrence
O	1417	1419	of
O	1420	1424	bone
O	1425	1435	metastases
O	1436	1438	or
O	1439	1448	fractures
O	1449	1451	in
O	1452	1460	patients
O	1461	1465	with
O	1466	1473	primary
O	1474	1480	breast
O	1481	1487	cancer
O	1488	1497	receiving
O	1498	1506	adjuvant
O	1507	1519	chemotherapy
O	1519	1520	.
